Topiramate Ocular Study (TOS)
Research type
Research Study
Full title
An observational study exploring the impact of topiramate on ocular structures in patients with headache
IRAS ID
201299
Contact name
Susanne Althauser
Contact email
Sponsor organisation
Royal Free Hospital NHS Foundation Trust
Clinicaltrials.gov Identifier
201299, IRAS
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
Topiramate is a commonly used treatment for migraine. It is well-known that this medication may have common ocular side effects with up to 10% clinically manifesting symptoms possibly leading to visual impairment. The mechanism behind how topiramate mediates these effects is poorly understood, especially in regards to dosing and titration. However, we hypothesize that subclinically, the impact of topiramate on the eye may be much higher. The aim of the study is to characterize the ocular changes induced by topiramate and thus identify the patients, who are most at risk.
Prospective participants will be healthy adults with migraine, who are commencing or discontinuing topiramate under the care of the Department of Neurology at the Royal Free Hospital. Participants will undergo ocular examination in conjunction with two simple non-invasive ophthalmic assessments - optical coherence tomography and biometry.
REC name
South East Scotland REC 02
REC reference
16/SS/0079
Date of REC Opinion
4 Apr 2016
REC opinion
Favourable Opinion